Last reviewed · How we verify
ZICONOTIDE ACETATE
Ziconotide acetate is a marketed drug primarily indicated for severe chronic pain management, currently holding a niche position in the pain management market. Its key strength lies in its unique mechanism of action, which differentiates it from opioid-based treatments. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | ZICONOTIDE ACETATE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Severe Chronic Pain Management
Boxed warnings
- WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms. WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS See full prescribing information for complete boxed warning Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Do not treat patients with a pre-existing history of psychosis with PRIALT
Common side effects
- Nausea
- Diarrhea
- Vertigo
- Vision Blurred
- Vomiting
- Asthenia
- Gait Abnormal
- Pyrexia
- Rigors
- Sinusitis
- Anorexia
- Muscle Spasms
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |